Role of Molecular Biology in the Prediction of Response to Neoadjuvant Treatment
In esophageal cancer, molecular markers representing tumor biological properties or patient features could provide significant determinants for predicting therapeutic response. To date, however, there is no sufficient evidence that current diagnostic methods can be used to improve the efficacy of multimodality neoadjuvant therapies. Molecular research in esophageal cancer has focused on two principal categories: (1) mRNA from cancer biopsies, searching for a relationship between outcome and the different gene expression levels; (2) DNA from healthy tissues, searching for associations between outcome and constitutive inter-individual genetic variations. This second option is a very attractive one, in that a small volume of peripheral blood is sufficient to obtain genomic DNA from lymphocytes-monocytes.
KeywordsEsophageal Cancer Esophageal Squamous Cell Carcinoma Esophageal Carcinoma Esophageal Squamous Cell Carcinoma Patient Cancer Biopsy
- 10.Gusella M, de Manzoni G, Marinelli R et al (2009) XPA and XRCC3 gene polymorphisms predict survival in esophageal cancer patients receiving neo-adjuvant radio-chemotherapy with cisplatin (CDDP), docetaxel (DTX) and 5-fluorouracil (FU). J Clin Oncol 27:e14571Google Scholar
- 13.Sarbia M, Stahl M, von Weyhern C et al (2006) The prognostic significance of genetic polymorphisms (Methylenetetrahydrofolate Reductase C677T, Methionine Synthase A2756G, Thymidilate Synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma. Br J Cancer 94:203–207PubMedCentralPubMedCrossRefGoogle Scholar
- 15.Jatoi A, Martenson JA, Foster NR et al (2007) Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044). Am J Clin Oncol. 30:507–513PubMedCrossRefGoogle Scholar